Abstract
GLIPTINS: SAME NEW DRUGS, NON-INFERIORITY OR NO SUPERIORITY
Dick B. S. Brashier*, Dr. Prashant Mishra, Htet Wai Moe, Kedar G. Bandekar, Neha Akhoon
ABSTRACT
Gliptins are a relatively new class of antidiabetic drugs that inhibits dipeptidyl peptidase-4 (DPP-4). They have revolutionized the treatment of type 2 diabetes mellitus as they changed the ways that diabetes and its management has been perceived by clinicians.[1] Gliptins modulate the physiological mechanism which is already in human body and increase the effect of incretin hormones, peptides which are normally released from the endocrine cells in small intestinal mucosa in response to food.
[Full Text Article] [Download Certificate]WJPLS CITATION
All | Since 2019 | |
Citation | 422 | 322 |
h-index | 9 | 7 |
i10-index | 4 | 2 |
INDEXING
NEWS & UPDATION
BEST PAPER AWARDS
World Journal of Pharmaceutical and life sciences Will give best paper award in every issue in the from of money along with certificate to promote research .
Best Article of current issue
Download Article : Click here